Citizens Maintains Market Outperform on IRulya Therapeutics, Raises Price Target to $86

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.